The VIGILANT Study
STUDY BASICS
Do you have moderate to severe COPD? You may be eligible for a research study to test an investigational drug called depemokimab compared to placebo as an add-on treatment for moderate to severe COPD, given as an injection. Study participation is expected to last 1-3 years during which there will be, on average, about one visit per month. Compensation is provided.
STUDY PURPOSE
This study is being done to test if depemokimab, compared to a placebo or an inactive substance, can improve COPD, make you feel better, is safe, well-tolerated, and works. The investigational medication is given in the form of a shot just under the skin.
COULD THIS STUDY BE RIGHT FOR YOU?
-
Are 40 to 75 years old
-
Have moderate to severe COPD
-
Are a current OR former smoker
-
Have had exactly one exacerbation (symptom flare-up) in the past 12 months that meet certain requirements
-
Have elevated levels of certain blood cells, known as eosinophils (E-O-SIN-O-FILS) that are known to be higher in some people who have COPD.
WHAT PARTICIPANTS CAN EXPECT
Participants will get either:
- The study drug, depemokimab, or
- An inactive substance (called a placebo). A placebo is an injection that does not have the active ingredient which may treat COPD.
Length of time in the study will vary by participant but is expected to last 1 to 3 years during which there will be, on average, about one visit per month.
https://pittplusme.org/study/vigilant